A 10-year microbiological study of Pseudomonas aeruginosa strains revealed the circulation of populations resistant to both carbapenems and quaternary ammonium compounds.
Humans
Carbapenems
/ pharmacology
Pseudomonas aeruginosa
Quaternary Ammonium Compounds
/ pharmacology
Membrane Transport Proteins
/ genetics
Anti-Bacterial Agents
/ pharmacology
beta-Lactamases
/ genetics
Dermatologic Agents
Pseudomonas Infections
/ microbiology
Microbial Sensitivity Tests
Drug Resistance, Multiple, Bacterial
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
received:
08
11
2022
accepted:
07
02
2023
entrez:
14
2
2023
pubmed:
15
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
Pseudomonas aeruginosa is one of the leading causes of healthcare-associated infections. For this study, the susceptibility profiles to antipseudomonal antibiotics and a quaternary ammonium compound, didecyldimethylammonium chloride (DDAC), widely used as a disinfectant, were established for 180 selected human and environmental hospital strains isolated between 2011 and 2020. Furthermore, a genomic study determined resistome and clonal putative relatedness for 77 of them. During the ten-year study period, it was estimated that 9.5% of patients' strains were resistant to carbapenems, 11.9% were multidrug-resistant (MDR), and 0.7% were extensively drug-resistant (XDR). Decreased susceptibility (DS) to DDAC was observed for 28.0% of strains, a phenotype significantly associated with MDR/XDR profiles and from hospital environmental samples (p < 0.0001). According to genomic analyses, the P. aeruginosa population unsusceptible to carbapenems and/or to DDAC was diverse but mainly belonged to top ten high-risk clones described worldwide by del Barrio-Tofiño et al. The carbapenem resistance appeared mainly due to the production of the VIM-2 carbapenemase (39.3%) and DS to DDAC mediated by MexAB-OprM pump efflux overexpression. This study highlights the diversity of MDR/XDR populations of P. aeruginosa which are unsusceptible to compounds that are widely used in medicine and hospital disinfection and are probably distributed in hospitals worldwide.
Identifiants
pubmed: 36788252
doi: 10.1038/s41598-023-29590-0
pii: 10.1038/s41598-023-29590-0
pmc: PMC9929048
doi:
Substances chimiques
Carbapenems
0
N,N-dimethyl-N-hexadecyl-1-octadecylammonium
32288-33-8
didecyldimethylammonium
Z7F472XQPA
Quaternary Ammonium Compounds
0
Membrane Transport Proteins
0
Anti-Bacterial Agents
0
beta-Lactamases
EC 3.5.2.6
Dermatologic Agents
0
Banques de données
figshare
['10.6084/m9.figshare.c.6293046']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2639Informations de copyright
© 2023. The Author(s).
Références
Antimicrob Agents Chemother. 2006 Jan;50(1):43-8
pubmed: 16377665
Antimicrob Agents Chemother. 1998 Feb;42(2):399-403
pubmed: 9527793
Antimicrob Agents Chemother. 2000 Dec;44(12):3322-7
pubmed: 11083635
Int J Antimicrob Agents. 2020 Dec;56(6):106196
pubmed: 33045347
Microbiology (Reading). 2012 Apr;158(Pt 4):1005-1015
pubmed: 22282518
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Front Microbiol. 2016 Sep 21;7:1483
pubmed: 27708632
PLoS One. 2015 Oct 06;10(10):e0139995
pubmed: 26440806
Front Cell Infect Microbiol. 2022 Jul 08;12:909731
pubmed: 35880080
J Mol Biol. 2015 Nov 20;427(23):3628-45
pubmed: 26319792
Microorganisms. 2021 Dec 10;9(12):
pubmed: 34946151
Am J Infect Control. 2015 May 1;43(5):424-34
pubmed: 25792102
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
APMIS. 2020 Mar;128(3):220-231
pubmed: 31709616
Curr Protoc Bioinformatics. 2020 Jun;70(1):e102
pubmed: 32559359
J Appl Microbiol. 2003;95(4):874-82
pubmed: 12969304
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33328175
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Antibiotics (Basel). 2022 Mar 21;11(3):
pubmed: 35326884
Exp Ther Med. 2020 Aug;20(2):762-769
pubmed: 32742322
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
Drug Resist Updat. 2019 May;44:100640
pubmed: 31492517
Pathogens. 2022 Dec 30;12(1):
pubmed: 36678412
Mol Biol Rep. 2021 Jun;48(6):5275-5281
pubmed: 34245410
Microb Genom. 2018 Mar;4(3):
pubmed: 29543149
J Clin Med. 2020 Nov 24;9(12):
pubmed: 33255354
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11
pubmed: 15793102
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Sci Rep. 2021 Jun 16;11(1):12728
pubmed: 34135355
Am J Kidney Dis. 2001 Feb;37(2):337-42
pubmed: 11157375
J Cyst Fibros. 2015 May;14(3):341-6
pubmed: 25443472
Nature. 2000 Aug 31;406(6799):959-64
pubmed: 10984043
Antimicrob Agents Chemother. 2001 Feb;45(2):546-52
pubmed: 11158753
J Clin Microbiol. 2016 Jul;54(7):1782-1788
pubmed: 27098958
PLoS One. 2011;6(12):e29113
pubmed: 22216178
Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2349-2361
pubmed: 34169445
Bioinformatics. 2013 Apr 15;29(8):1072-5
pubmed: 23422339
Am J Infect Control. 2018 Jul;46(7):e57-e63
pubmed: 29778432
Drug Discov Today. 2019 Jan;24(1):350-359
pubmed: 30036575
Appl Health Econ Health Policy. 2019 Jun;17(3):381-389
pubmed: 30506456
J Antimicrob Chemother. 2014 Jul;69(7):1804-14
pubmed: 24603963
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500
Clin Microbiol Rev. 2009 Oct;22(4):582-610
pubmed: 19822890
Front Microbiol. 2021 Feb 18;12:614058
pubmed: 33679638
J Clin Microbiol. 2012 Apr;50(4):1355-61
pubmed: 22238442